African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2281

Full Length Research Paper

In vivo assessment of the antipyretic activity of tilmicosin

A. M. El-Mahmoudy
  • A. M. El-Mahmoudy
  • Department of Pharmacology, Benha University, 13736 Moshtohor, Egypt.
  • Google Scholar
I. M. Gheith
  • I. M. Gheith
  • Department of Medical Laboratories Technology, Faculty of Applied Medical Sciences, Taibah University, 344 Medinah, Kingdom of Saudi Arabia.
  • Google Scholar
A. A. Elmajdoub
  • A. A. Elmajdoub
  • Department of Pharmacology, Toxicology and Forensic Medicine, University of Tripoli, 13662 Tripoli, Libya.
  • Google Scholar
S. K. Awidat
  • S. K. Awidat
  • Department of Pharmacology, Toxicology and Forensic Medicine, University of Tripoli, 13662 Tripoli, Libya.
  • Google Scholar


  •  Received: 26 February 2018
  •  Accepted: 10 April 2018
  •  Published: 15 April 2018

 ABSTRACT

The aim of the present study was to assess the antipyretic activity of the macrolide antibiotic, tilmicosin, at dose levels of 20 and 40 mg/kg of body weight, subcutaneously, in Brewer's yeast-induced fever model in mice. Pyrexia was induced by subcutaneous injection of 20 mL/kg of 20% (w/v) Brewer’s yeast suspension into the animal’s scruff region. Eighteen hours later, feverish animals were treated with either tilmicosin or acetylsalicylic acid (200 mg/kg injectable solution, subcutaneously) or vehicle; and rectal temperatures were evaluated at 1, 2, 3, 4 and 5 h post-treatment using digital thermometers. Tilmicosin showed dose-dependent significant decrease in the elevated body temperature of mice that remained sustained throughout the tested time points from 1 to 5 h in the used model. Both small and large dose levels showed a significant inhibition of elevated body temperature when compared with the corresponding febrile controls (37.65 ± 0.04 vs. 38.41 ± 0.08°C and 37.44 ± 0.04 vs. 38.44 ± 0.04, after 1 h; 37.19 ± 0.04 vs. 38.41 ± 0.08°C and 36.80 ± 0.03 vs. 38.44 ± 0.04°C after 5 h, respectively). These activities were standardized as 38.0 and 51.59% and 47.9 and 66.43% after 5 h, respectively, compared to that of the standard antipyretic and acetylsalicylic acid (200 mg/kg of body weight, subcutaneously). These results may indicate that tilmicosin, in addition to its well established antibacterial activity, possesses significant antipyretic activity that may be beneficial in symptomatic relief when it is used in therapy of infectious disease conditions and inflammatory disorders.
 
Key words: Antipyretic, tilmicosin, macrolides.


 INTRODUCTION

Fever is a well-known finding in almost all of infectious disease conditions and inflammatory disorders. Although uncomfortable, or even risky if 4 degrees over normal because of dehydration, strained heart and impaired respiration; however, it gives an alarm of warning of infection or a risk to the body. Mastering of fever besides treating the specific infectious agent that causes the disease is considered as a critical and important issue in therapy for safety and welfare of animal and human patient subjects. Classically, the genesis of fever or pyrexia; upon exposure to infectious agents as bacteria, viruses, fungi and some parasites or to mechanical injuries; is induced by inflammatory mediators (that is, prostaglandins and pro-inflammatory cytokines) that are released by affected tissue and activated immune cells (Ahrens, 1996; Roth, 2006). Within the brain, prostaglandin E2 (PGE2), produced by cyclooxygenase (COX)-2, is regarded as the principal mediator of fever (Aronoff and Neilson, 2001)acting on thermosensitive or thermointegrative hypothalamic neurons. Brewer’s yeast-induced pyrexia is the most common model for investigating the antipyretic potentials of unknown substances. It is an eukaryote and belongs to the fungus Saccharomyces cerevisiae that is single cellular spherical or ellipsoidal in shape. The yeast-induced fever (pathogenic fever) in mouse model was employed in the present study, to investigate the antipyretic activity of tilmicosin. An effective antipyretic is a drug or agent that can reduce fever or elevated body temperature. The word comes from the Ancient Greek (anti, against) and (pyreticus, pertaining to fever) (Merriam-Webster, 2014).
 
Antipyretics may interrupt pyrexogenesis at any step from periphery to heat regulating centres. Many well-known and approved antipyretics are established including aspirin, paracetamol, ibuprofen, diclofenac, etc., are prescribed together with specific drugs in fevers associated with inflammatory conditions caused by infectious and/or traumatic agents.  In addition to the standard and established common antipyretic agents, some other drugs may have antipyretic potentials besides their categorized main pharmacological actions and purposes. This finding may give the benefit of synergism when these potentially active drugs can be combined together with the standard ones; synergism may render, sometimes, therapy safer and more agreeable. Tilmicosin is a macrolide antibiotic with the chemical name of 20-deoxo-20-(3,5-dimethyl piperidin-1-yl) desmycosin. Macrolide class of antibiotics contain a macrocyclic lactone ring in their molecular structure; tilmicosin contains a 16-member one. The kinetic behaviour and properties of macrolide antimicrobials, that is, characterized by a distribution volume (Vd) allow to reach a high concentration in the target tissue (Biophase) even after administration of a small dose. Tilmicosin, among macrolide antimicrobials, is a bacteriostatic and works by penetrating the cell membrane of sensitive microbes and binding to the 50s ribosomal subunit, suppressing protein synthesis.
 
More precisely, the translocation of immature peptide chains between the 50 and 30s ribosomal subunits is interfered, this leads to early detachment and incomplete peptide chains are being synthesized (Seiple et al., 2016). Tilmicosin is an effective remedy for various Gram-positive organisms such as Corynebacterium and Listeria species, some Gram-negative bacteria, such as Pasteurella and Haemophilus species, as well as atypical bacteria as Mycoplasma species that infection by all of which is associated with fever. Tilmicosin is related to tylosin in its chemical structure, with the chemical formula of C46H80N2O13 and molecular weight of 869.15. From the physical point of view, it is freely soluble in organic solvents like hexane, acetone, acetonitrile, chloroform, dichloromethane, ethyl acetate, methanol, and tetrahydrofuran with solubility rate of 1500 mg/L or greater. Water solubility depends on temperature and pH; the solubility rate is about 566 mg/mL at pH 7 and 25°C. In a previous study, the antinociceptive potential of tilmicosin in mice have been proven against chemical but not thermal stimulai (El-Mahmoudy and Gheith, 2016). The objective targeted in the current study was the assessment of the antipyretic activity of tilmicosin on Brewer’s yeast induced fever in mice.


 MATERIALS AND METHODS

Fever is a well-known finding in almost all of infectious disease conditions and inflammatory disorders. Although uncomfortable, or even risky if 4 degrees over normal because of dehydration, strained heart and impaired respiration; however, it gives an alarm of warning of infection or a risk to the body. Mastering of fever besides treating the specific infectious agent that causes the disease is considered as a critical and important issue in therapy for safety and welfare of animal and human patient subjects. Classically, the genesis of fever or pyrexia; upon exposure to infectious agents as bacteria, viruses, fungi and some parasites or to mechanical injuries; is induced by inflammatory mediators (that is, prostaglandins and pro-inflammatory cytokines) that are released by affected tissue and activated immune cells (Ahrens, 1996; Roth, 2006). Within the brain, prostaglandin E2 (PGE2), produced by cyclooxygenase (COX)-2, is regarded as the principal mediator of fever (Aronoff and Neilson, 2001)acting on thermosensitive or thermointegrative hypothalamic neurons. Brewer’s yeast-induced pyrexia is the most common model for investigating the antipyretic potentials of unknown substances. It is an eukaryote and belongs to the fungus Saccharomyces cerevisiae that is single cellular spherical or ellipsoidal in shape. The yeast-induced fever (pathogenic fever) in mouse model was employed in the present study, to investigate the antipyretic activity of tilmicosin. An effective antipyretic is a drug or agent that can reduce fever or elevated body temperature. The word comes from the Ancient Greek (anti, against) and (pyreticus, pertaining to fever) (Merriam-Webster, 2014).
 
Antipyretics may interrupt pyrexogenesis at any step from periphery to heat regulating centres. Many well-known and approved antipyretics are established including aspirin, paracetamol, ibuprofen, diclofenac, etc., are prescribed together with specific drugs in fevers associated with inflammatory conditions caused by infectious and/or traumatic agents.  In addition to the standard and established common antipyretic agents, some other drugs may have antipyretic potentials besides their categorized main pharmacological actions and purposes. This finding may give the benefit of synergism when these potentially active drugs can be combined together with the standard ones; synergism may render, sometimes, therapy safer and more agreeable. Tilmicosin is a macrolide antibiotic with the chemical name of 20-deoxo-20-(3,5-dimethyl piperidin-1-yl) desmycosin. Macrolide class of antibiotics contain a macrocyclic lactone ring in their molecular structure; tilmicosin contains a 16-member one. The kinetic behaviour and properties of macrolide antimicrobials, that is, characterized by a distribution volume (Vd) allow to reach a high concentration in the target tissue (Biophase) even after administration of a small dose. Tilmicosin, among macrolide antimicrobials, is a bacteriostatic and works by penetrating the cell membrane of sensitive microbes and binding to the 50s ribosomal subunit, suppressing protein synthesis.
 
More precisely, the translocation of immature peptide chains between the 50 and 30s ribosomal subunits is interfered, this leads to early detachment and incomplete peptide chains are being synthesized (Seiple et al., 2016). Tilmicosin is an effective remedy for various Gram-positive organisms such as Corynebacterium and Listeria species, some Gram-negative bacteria, such as Pasteurella and Haemophilus species, as well as atypical bacteria as Mycoplasma species that infection by all of which is associated with fever. Tilmicosin is related to tylosin in its chemical structure, with the chemical formula of C46H80N2O13 and molecular weight of 869.15. From the physical point of view, it is freely soluble in organic solvents like hexane, acetone, acetonitrile, chloroform, dichloromethane, ethyl acetate, methanol, and tetrahydrofuran with solubility rate of 1500 mg/L or greater. Water solubility depends on temperature and pH; the solubility rate is about 566 mg/mL at pH 7 and 25°C. In a previous study, the antinociceptive potential of tilmicosin in mice have been proven against chemical but not thermal stimulai (El-Mahmoudy and Gheith, 2016). The objective targeted in the current study was the assessment of the antipyretic activity of tilmicosin on Brewer’s yeast induced fever in mice.
 
 
 
 
Brewer’s yeast-induced pyrexia model
 
The method described by Tomazetti et al. (2005)was adopted with minor modifications to test the antipyretic activity of tilmicosin in mice. After recording the rectal temperature of each of the animal using a small sized digital thermometer digital thermometer (9SK-1250 MC, Sato Keiryoki Mfg Co. Ltd., Japan), pyrexia was induced by subcutaneous injection of 20 mL/kg of 20% (w/v) Brewer’s yeast (Sigma-Aldrich, St. Louis, USA) suspension into the animal’s scruff region. Animals were then fasted and 18 h later, the rectal temperature of each animal was re-measured and recorded. Only mice showing an increase in temperature of at least 1°C were used for experiment. Feverish animals were treated with either tilmicosin or standard or vehicle as described earlier; and rectal temperatures were measured at 1, 2, 3, 4 and 5 h post-treatment. Temperature readings of the second group at these different time points were compared to those of the first group; while the readings of the third, fourth and fifth groups were compared to those of the second group at the same time points. Percentage reduction in rectal temperature (antipyresis) was calculated using the following equation:
 
% Reduction = (B – Tn / B – Cn) × 100
 
where n is the time point = 1, 2, 3, 4 and 5; B is the Brewer’s feverish temperature; T is the treated temperature; C is the control temperature.
 
Data presentation and statistical analysis
 
 
All data are expressed as Mean ± standard error of mean (SEM) of eight observations (n = 8). Comparison among control and treated groups (small and large doses) were analysed for significance using a one-way analysis of variance (ANOVA) followed by least significant difference (LSD) test as a post-hoc. P-values of 0.05 or less were considered significant. The antipyretic potential of tilmicosin has been, in addition, standardized as % comparable to that of acetylsalicylic acid (standard antipyretic agent). All calculations and procedures of data statistical analysis were carried out using the computer programme SPSS v20 software.

 

 

 

 


 RESULTS

Animals received tilmicosin 20 or 40 mg/kg of body weight exhibited localized tender swellings at the site of subcutaneous injection of both tested doses. Results of the adopted antipyretic test were recorded as the following. The results of the antipyretic assay of the test (tilmicosin, 20 and 40 mg/kg, SC) and standard (ASA, 200 mg/kg, SC) drugs, as well as those of the control are shown in Table 1 and depicted in Figure 2. Normal rectal temperatures of mice ranged between 36.43 and 36.55°C. All Brewer’s yeast suspension-injected animals became feverish after 18 h with rectal temperature range of 38.2 to 38.44°C. Vehicle-treated animals remained feverish until the end of the experimental period. On the other hand, ASA (200 mg/kg of body weight, subcutaneously) as well as tilmicosin (20 and 40 mg/kg of body weight, subcutaneously) have shown effective significant reduction of the elevated rectal body temperatures at all of the tested time points (1 to 5 h) post-administration as compared to the feverish control (P < 0.05; ANOVA followed by LSD test). Antipyresis percentage of tilmicosin and those of the standard ASA are shown in Table 2. 
 
 
 
 


 DISCUSSION

The chemotherapeutic group of macrolides has been long-used class of antimicrobials and still play an important role in treatment of many diseases caused by sensitive microbes. As they are effective in infective diseases caused by pathogens, intracellularly-penetrating in particular, encouraged the drug specialists for the development of newer derivatives with improved kinetics, dynamics and tolerance (Seiple et al., 2016). However, the penetrating power and the ability of this drug group to accumulate intracellularly (Labro, 1993)may, in addition, cause some alterations in the host cell functions with new interests in their pharmacologic and therapeutic potentials other than antimicrobial one (Bryskier et al., 2008). The macrolide antibiotic tilmicosin is a tylosin-derivative being used in treatment of respiratory diseases in different animal species. Despite the inflammatory modulating potential of macrolide members, particularly that of erythromycin, has been reported (Labro, 1998; Steel et al., 2012), however, there is no, at least for our information, any data reported about antipyretic potential of this drug group. Normal body temperature is circadian and varies within about 0.5°C below and above from the morning to the late afternoon (Faull et al., 2015; Hunskaar and Hole, 1987). Thermoregulation is managed by integrated network of neural connections within CNS orchestrated in an area in the hypothalamus named the “preoptic area” which includes the preoptic nuclei located in the anterior hypothalamus (POAH). Simply, the POAH keeps mean body temperature around a particular set-point that is a characteristic for every species. Such normal set-point temperature could be modulated by the balance between functional activities of temperature-sensitive neurons. Such neurons integrate degrees of temperature according to afferent signals from inside the body and its periphery (skin) and evoke various behavioural and physiologic responsive activities integrating heat gain or heat loss (Mackowiak, 1997; Vriens et al., 2014).
 
Fever or pyrexia is an abnormal rise in the body temperature after an induced increase in the thermos-neutral set-point (Mateusen et al., 2001)by various causes as infections, tissue damages and inflammatory disorders. Upon setting temperature to a higher degree in the hypothalamus, the actual body temperature becomes lower that was set centrally. Consequently, and under the control of the hypothalamus, body physiological and behavioural functional activities favouring heat gain and retention are stimulated until arriving the body at the newly induced raised set-point temperature. Behavioural alterations including shelter seeking and grouping (animals) or adding clothes (human) and physiological alterations, including goose skin, peripheral vasoconstriction, shivering, and non-shivering thermogenesis via enhanced release of thyroid, glucocorticoid and catecholamine hormones occur till achieving the raised set-point of body temperature. Now, a condition of fever or pyrexia becomes settled as the thermoregulation mechanism modulates at this higher set point. Pathophysiological mediators (and hence the pharmacological targets) underlying pyrexia have been described. Endogenous pyrogens including pyrogenic cytokines, like interleukin-1β, tumour necrosis factor (TNF), and interleukin-6, are among those that are acting directly on the hypothalamus to modulate a feverish response (Croft et al., 2000). Exogenous pyrogens, such as surface components of microbes as lipopolysaccharides lipopolysaccharides (LPS), induce fever most probably via induction of pyrogenic cytokines capable of functioning at the level of the hypothalamus, in the same way as interleukin-1β (Ramadan, 1997). These signals trigger the release of other mediators, most notably PGE2, in the region of the POAH (Mateusen et al., 2001). Among prostaglandins, PGE2 has been proved to be the downstream mediator of the feverish response. Pre-optic neurons have, on their membranes, E-prostanoid receptors that alter their intrinsic firing rate upon its activation by PGE2, with a result of an elevated febrile set point. Four cellular receptors for PGE2: EP1 through EP4 were proved and reported (McKay et al., 1996; Mora et al., 2013). However, the specific receptor subtype involved in pyrogenesis is still not yet understood.
 
PGE2 is produced from its precursor arachidonic acid, which is freed from the injured phospholipid cell membranes by phospholipase-A2 (PLA2). Arachidonic acid is a substrate metabolized by COX enzyme that has two isoforms, COX-1 and COX-2. The isoform COX-1 is, usually, expressed constitutively and produces prostanoids important for some housekeeping functions supporting homeostasis as gastric mucosal integrity and renal artery blood flow (Simon, 1999). While the second isoform, COX-2, on the other hand, is inducible by inflammatory signals such as the pyrogenic cytokines, interleukin-1β, tumour necrosis factor, and interleukin-6, and bacterial lipopolysaccharide (Simon, 1999). The most likely cell type in the central nervous system responsible for producing PGE2 is the microvascular endothelial cell, which expresses COX-2 abundantly after stress (Cao et al., 1996). Fever is regulated by the body immune response. Therefore, on the other hand, release of endogenous antipyretic substances is provoked (Jordan et al., 1999)like arginine anti-diuretic hormone (vasopressin), melanocyte stimulating hormone (MSH), interleukin-10 and glucocorticoids act both centrally and peripherally to limit pyrexia. Besides, a group of lipid substances known as epoxy-eicosanoids produced by certain cytochrome P-450 enzymes play an important role in limiting the fever and inflammation (Mackowiak, 2000). Moreover, fever itself appears to counter the release of pyrogenic cytokines (Mackowiak, 1997).  An effective antipyretic may suppress peripheral inflammation and/or central pyrogenic signals. Suppressing central production of PGE2 is a well-established mechanism of antipyretic drugs, however, stimulated leukocytic and endothelial cells in peripheral inflammatory areas also constitute potential peripheral drug target(s). Two hypotheses may explain the mechanism of antipyretics; the cyclooxygenase-dependent hypothesis and the cyclooxygenase-nondependent hypothesis. In the former, the action of an antipyretic is mediated by inhibiting the production of prostaglandins via inhibiting COX as aspirin (Xu et al., 1999). Inhibition of COX-2 by aspirin as well as other
 
NSAID occur via inhibiting its transcription by interrupting a transcriptional activator, named, nuclear factor-kB (NF-kB) (Xu et al., 1999). NF-kB (normally kept inactive in the cytoplasm another protein named IkB) is a heterodimeric protein capable of binding DNA of many genes that are involved in the signalling pathway of inflammatory response. Once involved, NF-kB promotes the transcription of genes encoding pyrogenic cytokines (Kirtikara et al., 2000). The non-cyclooxygenase hypothesis indicates that actions of antipyretics may also be mediated by suppressing tissue inflammation by diminishing leukocyte-endothelial cell interactions (Pierce et al., 1996), reducing pyrogenic cytokine production (Ahrens, 1996), enhancing expression of anti-inflammatory molecules (Ahrens, 1996)or boosting the activity of endogenous antipyretic messengers (Wilkinson and Kasting, 1990). In the Brewer’s yeast-induced pyrexia model, it was found that rectal temperature as well as the percentage of its reduction exhibited by tilmicosin at dose levels of 20 and 40 mg/kg body weight after yeast injection was quite noticeable and comparable to the standard ASA group. The observed antipyretic effect was found to be sustained and lasted up to at least 5 h after single subcutaneous administrations of the drug samples which showed dose-dependent pattern of antipyretic efficacy. The antipyretic effect of tilmicosin might be due to interruption of pyrexogenesis at any step that connects peripheral inflammation with the central production of PGE2. Although there is no data that supports this speculation, yet the anti-inflammatory effect of macrolides has been reviewed by Labro (1998) who reported that the macrolide antimicrobial drugs have immuno-modulatory potentials; where in-vitro data suggested that derivatives of erythromycin may have a direct effect on neutrophil function with altered generation of cytokines involved in the inflammation pathway. In addition, ex-vivo data indicated that short-term administration of macrolide(s) might increase the immune response while its long-term administration, in contrast, might result in immuno-suppression. Further studies are needed to improve the current concepts of the pharmacology and therapeutics of macrolides. 


 CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

 



 REFERENCES

Ahrens FA (1996). Pharmacology. 1st, Wiley, Iowa ed: Wiley. P 328.

 

Aronoff DM, Neilson EG (2001). Antipyretics: mechanisms of action and clinical use in fever suppression. Am. J. Med. 111:304-315.
Crossref

 
 

Bryskier A, Agouridas C, Chantot JF (2008). New medical targets for macrolides. Expert Opin. Invest. Drugs 3:405-410.
Crossref

 
 

Cao C, Matsumura K, Yamagata K, Watanabe Y (1996). Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1β: a possible site of prostaglandin synthesis responsible for fever. Brain Res. 733:263-272.
Crossref

 
 

Croft A, Duffield T, Menzies P, Leslie K, Bagg R, Dick P (2000). The effect of tilmicosin administered to ewes prior to lambing on incidence of clinical mastitis and subsequent lamb performance. Can. Vet. J. 41:306.

 
 

El-Mahmoudy A, Gheith I (2016). The anti-nociceptive potential of tilmicosin against chemical-induced but not thermal-induced pain in mice. Int. J. Immunopathol. Pharmacol. 29:9-16.
Crossref

 
 

Faull O, Cotter J, Lucas S (2015). Cerebrovascular responses during rowing: Do circadian rhythms explain morning and afternoon performance differences? Scand. J. Med. Sci. Sports 25:467-475.
Crossref

 
 

Hunskaar S, Hole K (1987). The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 30:103-114.
Crossref

 
 

Jordan F, Forrester C, Hodge A, Reeve-Johnson L (1999). The comparison of an aqueous preparation of tilmicosin with tylosin in the treatment of Mycoplasma gallisepticum infection of turkey poults. Avian Disease. pp. 521-525.
Crossref

 
 

Kirtikara K, Raghow R, Laulederkind SJ, Goorha S, Kanekura T, Ballou LR (2000). Transcriptional regulation of cyclooxygenase-2 in the human microvascular endothelial cell line, HMEC-1: control by the combinatorial actions of AP2, NF-IL-6 and CRE elements. Mol. Cell. Biochem. 203:41-51.
Crossref

 
 

Labro M (1993). Intraphagocytic penetration of macrolide antibiotics. Macrolides: chemistry, pharmacology and clinical use. Arnette-Blackwell, Paris, France pp. 379-388.

 
 

Labro MT (1998). Anti-inflammatory activity of macrolides: a new therapeutic potential? J. Antimicrob. Chemother. 41:37-46.
Crossref

 
 

Mackowiak PA (1997). Fever: basic mechanisms and management. 2nd ed: Lippincott-Raven Publishers. P 506.

 
 

Mackowiak PA (2000). Temperature regulation and the pathogenesis of fever. Princip. Pract. Infect. Dis. 6:703-718.

 
 

Mateusen B, Maes D, Hoflack G, Verdonck M, De Kruif A (2001). A comparative study of the preventive use of tilmicosin phosphate (Pulmotil premix®) and Mycoplasma hyopneumoniae vaccination in a pig herd with chronic respiratory disease. J. Vet. Med. B. 48:733-741.
Crossref

 
 

McKay S, Morck D, Merrill J, Olson M, Chan S, Pap K (1996). Use of tilmicosin for treatment of pasteurellosis in rabbits. Am. J. Vet. Res. 57:1180-1184.

 
 

Merriam-Webster (2014). Definition of antipyretic [12-2014]. Available from: 

View

 
 

Mora N, Uribe-Querol E, Rosales C (2013). Molecular Aspects of Inflammation. In: Pérez-Martínez L, Pedraza-Alva G, Osorio EF, editors. Research signpost. Kerala, India: Research Signpost. pp.15-41.

 
 

Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T (1996). Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J. Immunol. 156:3961-3969.

 
 

Ramadan A (1997). Pharmacokinetics of tilmicosin in serum and milk of goats. Res. Vet. Sci. 62:48-50.
Crossref

 
 

Roth J (2006). Endogenous antipyretics. Clin. Chim. Acta 371:13-24.
Crossref

 
 

Seiple IB, Zhang Z, Jakubec P, Langlois-Mercier A, Wright PM, Hog DT, Yabu K, Allu SR, Fukuzaki T, Carlsen PN (2016). A platform for the discovery of new macrolide antibiotics. Nature 533:338.
Crossref

 
 

Simon LS (1999). Role and regulation of cyclooxygenase-2 during inflammation. Am. J. Med. 106:37S-42S.
Crossref

 
 

Steel HC, Theron AJ, Cockeran R, Anderson R, Feldman C (2012). Pathogen-and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm. 2012:584262.
Crossref

 
 

Tomazetti J, Ávila DS, Ferreira APO, Martins JS, Souza FR, Royer C, Rubin MA, Oliveira MR, Bonacorso HG, Martins MAP (2005). Baker yeast-induced fever in young rats: Characterization and validation of an animal model for antipyretics screening. J. Neurosci. Methods 147:29-35.
Crossref

 
 

Vriens J, Nilius B, Voets T (2014). Peripheral thermosensation in mammals. Nat. Rev. Neurosci. 15:573.
Crossref

 
 

Wilkinson MF, Kasting NW (1990). Central vasopressin V1-blockade prevents salicylate but not acetaminophen antipyresis. J. Appl. Physiol. 68:1793-1798.
Crossref

 
 

Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK (1999). Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc. Natl. Acad. Sci. 96:5292-5297.
Crossref

 
 

 




          */?>